Pierce Biotechnology

Beacon Biosignals Names Biotech Veteran Christine Vietz as Chief R&D Officer

Retrieved on: 
Wednesday, April 12, 2023
Epilepsy, Ferdinand Bernhard Vietz, University, Doctor of Philosophy, Biotechnology, Joint Planning and Development Office, DSM-IV codes, Patient, Chemical engineering, EEG, Medicine, Foundation Medicine, Sleep, Pierce Biotechnology, Safety, Pharmaceutical industry, Management, Beacon

BOSTON, April 12, 2023 /PRNewswire/ -- Beacon Biosignals, a world leader in machine learning-enabled electroencephalogram (EEG) and clinical outcome analysis, today announced it has named biotechnology industry veteran Christine Vietz, Ph.D., as Chief Research and Development Officer.

Key Points: 
  • BOSTON, April 12, 2023 /PRNewswire/ -- Beacon Biosignals, a world leader in machine learning-enabled electroencephalogram (EEG) and clinical outcome analysis, today announced it has named biotechnology industry veteran Christine Vietz, Ph.D., as Chief Research and Development Officer.
  • Vietz comes to Beacon from Cambridge, Massachusetts-based diagnostics firm Foundation Medicine, Inc., where she worked for over 10 years.
  • "I'm excited to tackle the challenge of advancing precision medicine for neurological and psychiatric disorders," Vietz said.
  • Prior to working at Foundation Medicine, Vietz was employed at several biotech companies in the Boston area, including Progenika, Correlagen Diagnostics, and Pierce Biotechnology.

Thermo Fisher Scientific to Present at 41st Annual Cowen Healthcare Conference on March 3, 2021

Retrieved on: 
Wednesday, February 24, 2021
Companies, Economy of the United States, Industry economics), Thermo Fisher Scientific, Applied Biosystems, Invitrogen, Patheon, Thermo, Fisher Scientific, Waltham, Massachusetts, Fermentas, Pierce Biotechnology

WALTHAM, Mass., Feb. 24, 2021 /PRNewswire/ --Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science,announced that Marc N. Casper, chairman, president and chief executive officer, will present virtually at the 41st Annual Cowen Healthcare Conference on Wednesday, March 3, 2021, at 10:20 a.m. (EDT).

Key Points: 
  • WALTHAM, Mass., Feb. 24, 2021 /PRNewswire/ --Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science,announced that Marc N. Casper, chairman, president and chief executive officer, will present virtually at the 41st Annual Cowen Healthcare Conference on Wednesday, March 3, 2021, at 10:20 a.m. (EDT).
  • You can access the webcast of the presentation via the Investors section of our website, www.thermofisher.com .
  • Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $30 billion.
  • Our global team of more than 80,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon.

Thermo Fisher Scientific Recognized with Six CMO Leadership Awards

Retrieved on: 
Thursday, February 18, 2021
Thermo Fisher Scientific, Thermo, Companies, Waltham, Massachusetts, Mergers and acquisitions, Economy of the United States, Pierce Biotechnology

WALTHAM, Mass., Feb. 18, 2021 /PRNewswire/ -- Thermo Fisher Scientific, the world leader in serving science, today announced it has won six awards in the annual CMO Leadership Awards.

Key Points: 
  • WALTHAM, Mass., Feb. 18, 2021 /PRNewswire/ -- Thermo Fisher Scientific, the world leader in serving science, today announced it has won six awards in the annual CMO Leadership Awards.
  • This is the second consecutive year Thermo Fisher has received this recognition across all six categories and eighth time overall that the company has been honored by the CMO Leadership Awards.
  • "This year more than ever, Thermo Fisher is proud to be recognized for our ability to serve our biopharma and biotech customers with speed, flexibility and scale," said Mike Shafer, senior vice president and president, pharma services, Thermo Fisher Scientific.
  • Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $30 billion.

Thermo Fisher Scientific and Lyell Immunopharma Form Cell Therapy Manufacturing Partnership

Retrieved on: 
Tuesday, July 28, 2020
Companies, Thermo Fisher Scientific, Industries, Thermo, Fisher Scientific, Waltham, Massachusetts, Science and technology, Pierce Biotechnology

WALTHAM, Mass., July 28, 2020 /PRNewswire/ -- Thermo Fisher Scientific Inc., the world leader in serving science, and biotechnology company Lyell Immunopharma, are partnering to develop manufacturing processes designed to create more effective cell therapies to benefit cancer patients.

Key Points: 
  • WALTHAM, Mass., July 28, 2020 /PRNewswire/ -- Thermo Fisher Scientific Inc., the world leader in serving science, and biotechnology company Lyell Immunopharma, are partnering to develop manufacturing processes designed to create more effective cell therapies to benefit cancer patients.
  • "Significant investment is being put toward understanding T cell biology, and Lyell has put together an impressive team to accelerate research and development that benefits the entire industry," said Mark Stevenson, executive vice president and chief operating officer, Thermo Fisher Scientific.
  • "Thermo Fisher offers the ideal combination of cell manufacturing technologies and as-needed capacity to enable accelerated product development and growth."
  • Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $25 billion.